- Home
- TGTX vs AXSM Comparison
TGTX vs AXSM Comparison
Compare TGTX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- AXSM
- Stock Information
- Founded
- TGTX 1993
- AXSM 2012
- Country
- TGTX United States
- AXSM United States
- Employees
- TGTX N/A
- AXSM N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- TGTX Health Care
- AXSM Health Care
- Exchange
- TGTX Nasdaq
- AXSM Nasdaq
- Market Cap
- TGTX 5.5B
- AXSM 5.9B
- IPO Year
- TGTX 1995
- AXSM 2015
- Fundamental
- Price
- TGTX $33.65
- AXSM $127.79
- Analyst Decision
- TGTX Strong Buy
- AXSM Strong Buy
- Analyst Count
- TGTX 6
- AXSM 19
- Target Price
- TGTX $47.50
- AXSM $174.47
- AVG Volume (30 Days)
- TGTX 1.5M
- AXSM 433.3K
- Earning Date
- TGTX 11-04-2025
- AXSM 11-03-2025
- Dividend Yield
- TGTX N/A
- AXSM N/A
- EPS Growth
- TGTX N/A
- AXSM N/A
- EPS
- TGTX 0.36
- AXSM N/A
- Revenue
- TGTX $454,069,000.00
- AXSM $495,033,000.00
- Revenue This Year
- TGTX $82.13
- AXSM $63.76
- Revenue Next Year
- TGTX $49.01
- AXSM $54.57
- P/E Ratio
- TGTX $92.64
- AXSM N/A
- Revenue Growth
- TGTX 30.96
- AXSM 69.83
- 52 Week Low
- TGTX $22.61
- AXSM $75.56
- 52 Week High
- TGTX $46.48
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- TGTX 48.14
- AXSM 58.76
- Support Level
- TGTX $34.01
- AXSM $127.49
- Resistance Level
- TGTX $35.52
- AXSM $134.25
- Average True Range (ATR)
- TGTX 1.28
- AXSM 4.19
- MACD
- TGTX -0.24
- AXSM 0.57
- Stochastic Oscillator
- TGTX 16.02
- AXSM 61.88
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.